Real-world study on the safety and efficacy of standard dose hetrombopag olamine tablets in the treatment of aplastic anemia

Phase 4

• Conditions: Aplastic anemia

• Registration Number: ChiCTR2400088990
• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Patients sign informed consent, voluntarily join the study, and have the willingness and ability to cooperate with the data collection in this study;<br>2. The clinical diagnosis was non-severe aplastic anemia.<br>3. To receive standard dose of herombopag (15mg);

Exclusion Criteria

1. Secondary aplastic anemia after treatment of malignant tumor;<br>2. The patient is undergoing or planning to enroll in a clinical intervention study;<br>3. Other situations deemed unsuitable for inclusion in the study by the researcher.

Study & Design

• Study Type: Observational study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The incidence and degree of hepatic and renal dysfunction in 4 to 6 months after treatment with standard dose of herombopag;Proportion of patients receiving hematologic response within 4-6 months of treatment with standard dose of herombopag;

Secondary Outcome Measures

Name	Time	Method
Quality of hematological remission within 4-6 months of treatment with standard dose of hexapopal.;All patients were observed for any adverse events after treatment with standard dose of hexapopal;